Beyond Air, Inc. will report financial results for its second fiscal quarter on November 10, 2025. The company focuses on using nitric oxide to improve patient lives. A conference call and webcast will be hosted by the management team at 4:30 pm Eastern Time on the same day. Details for the call can be found on the company’s website.

Beyond Air is a medical device company using nitric oxide to treat respiratory illnesses, neurological disorders, and tumors. The company’s first system, LungFit® PH, received FDA approval for treating neonates with hypoxic respiratory failure. Beyond Air is also conducting clinical trials for treating severe lung infections like COVID-19.

Beyond Air has a partnership with The Hebrew University of Jerusalem for a pre-clinical program on autism spectrum disorder. Additionally, Beyond Cancer, Ltd. is researching high concentrations of NO to target solid tumors. The company emphasizes using nitric oxide for various therapeutic benefits and innovative treatments across different medical conditions.

The press release contains forward-looking statements regarding the safety and efficacy of nitric oxide products and their potential therapeutic uses. These statements are based on expectations and beliefs related to product offerings and business strategies. Actual results may differ due to factors like regulatory approval, clinical trial results, and intellectual property protection.

For more information, contact Corey Davis, Ph.D. from LifeSci Advisors, LLC at [email protected] or (212) 915-2577. Stay updated with Beyond Air’s latest news and developments by visiting their website.

Read more at GlobeNewswire: Beyond Air Schedules Second Fiscal Quarter 2026 Financial